C. Gourley

Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas

David S.P. Tan, Marjan Iravani, W. Glenn McCluggage et al. · Clinical Cancer Research · 2011 · 144 citations

Medicine, Biostatistics, Cancer Genetics +8

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

Peter C.C. Fong, David S. Boss, C. P. Carden et al. · Journal of Clinical Oncology · 2008 · 83 citations

Medicine, Oncology, Pharmacology +17

Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Jonathan A. Ledermann, Philipp Harter, C. Gourley et al. · Journal of Clinical Oncology · 2011 · 58 citations

Medicine, Oncology, Pharmacology +14

Routine germline <i><scp>BRCA</scp>1</i> and <i><scp>BRCA</scp>2</i> testing in patients with ovarian carcinoma: analysis of the Scottish real‐life experience

K. Rust, Pavlina Spiliopoulou, CY Tang et al. · BJOG An International Journal of Obstetrics & Gynaecology · 2018 · 31 citations · Full text

Medicine, Genetics, Oncology +17

435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Darren Hodgson, Brian Dougherty, Zefeng Lai et al. · European Journal of Cancer · 2015 · 25 citations · Full text

Medicine, Cancer Biology, Oncology +17